Brokerages Anticipate Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) to Post -$0.35 EPS
Wall Street brokerages expect that Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) will announce earnings per share (EPS) of ($0.35) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Adaptimmune Therapeutics’ earnings. The lowest EPS estimate is ($0.40) and the highest is ($0.29). Adaptimmune Therapeutics reported earnings of ($0.48) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 27.1%. The firm is scheduled to announce its next earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Adaptimmune Therapeutics will report full-year earnings of ($1.17) per share for the current fiscal year, with EPS estimates ranging from ($1.34) to ($0.94). For the next year, analysts expect that the company will report earnings of ($1.16) per share, with EPS estimates ranging from ($1.45) to ($0.83). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Adaptimmune Therapeutics.
Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative return on equity of 45.03% and a negative net margin of 161.09%.
Hedge funds have recently made changes to their positions in the stock. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of Adaptimmune Therapeutics by 8.7% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 28,621 shares of the biotechnology company’s stock worth $123,000 after buying an additional 2,280 shares during the last quarter. Raymond James & Associates lifted its position in shares of Adaptimmune Therapeutics by 59.0% during the 4th quarter. Raymond James & Associates now owns 22,906 shares of the biotechnology company’s stock worth $132,000 after buying an additional 8,498 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Adaptimmune Therapeutics during the 4th quarter worth $622,000. Deutsche Bank AG lifted its position in shares of Adaptimmune Therapeutics by 1,681,328.6% during the 4th quarter. Deutsche Bank AG now owns 117,700 shares of the biotechnology company’s stock worth $676,000 after buying an additional 117,693 shares during the last quarter. Finally, Rathbone Brothers plc lifted its position in shares of Adaptimmune Therapeutics by 27.9% during the 1st quarter. Rathbone Brothers plc now owns 285,722 shares of the biotechnology company’s stock worth $1,229,000 after buying an additional 62,292 shares during the last quarter. Institutional investors and hedge funds own 66.30% of the company’s stock.
NASDAQ ADAP traded up $0.17 during trading on Friday, hitting $3.18. The stock had a trading volume of 239,323 shares, compared to its average volume of 191,255. Adaptimmune Therapeutics has a 12 month low of $2.94 and a 12 month high of $14.54. The firm has a market cap of $315.12 million, a P/E ratio of -3.31 and a beta of 1.63. The company has a debt-to-equity ratio of 0.12, a current ratio of 8.55 and a quick ratio of 8.55. The company has a 50-day moving average price of $3.60.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Featured Story: P/E Growth (PEG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.